Itovebi: Dosage Form, Projected Sales, NCE-1 Date | Inavolisib

Itovebi

Itovebi is an oral targeted therapy, added to palbociclib and fulvestrant, for HR-positive, HER2-negative advanced breast cancer with PIK3CA mutations. It inhibits mutant PI3Kα to slow tumor progression and extend progression-free survival.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Inavolisib
Innovator :

GENENTECH INC
Approval Date :

10-Oct-24
NCE-1 Date :

10-Oct-28
NCE Date :

10-Oct-29
Dosage Form :

Oral Tablets
Strength :

3mg and 9mg
Therapeutic Category :

Anticancer
Revenue ($M) :

9

Year-wise Projected Sales ($M) :

2025 :

157
2026 :

396
2027 :

692
2028 :

990
2029 :

1,321
2030 :

1,626
2031 :

1,908

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Itovebi

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?